Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

40 hours with a standard deviation of .37 hours. "Early recognition of patients with cardiogenic shock allows for prompt treatment initiation," the study authors wrote. "Timely intervention can ...

A cardiovascular specialty hospital in north Texas decreased time to diagnosis for patients with cardiogenic shock by more ...

The patent filing expands upon data obtained from animal model testing and the istaroxime human clinical trials in acute heart failure (AHF) and early cardiogenic shock (ECS), including the latest ...

Windtree, in documents filed with the Securities and Exchange Commission, said it does not have sufficient cash to support its operations for the next year. The CEO of Windtree Therapeutics is ...

Phase 1 results support further evaluation of ALLO-316 in patients with CD70-positive clear cell renal cell carcinoma, according to researchers.

Danvers: Johnson & Johnson MedTech, has announced that the U.S. Food and Drug Administration (FDA) has expanded the ...

Windtree Therapeutics (WINT) announced that it has filed a new istaroxime PCT patent application entitled, “ISTAROXIME DERIVATIVES THEREOF FOR ...

[Impact of VA-ECMO combined with IABP and timing on outcome of patients with acute myocardial infarction complicated with cardiogenic shock ... repair system in the treatment of patients ...